FDA seeking comments on biosimilars user fee program

FDA is accepting comments on a proposed biosimilars user fee program under which sponsors would be able to obtain an SPA for the development of a biosimilar. FDA will hold a public meeting on Dec. 16 to discuss the program. Comments are due within 30 days of the proposal's publication in the Federal Register, which FDA expects Wednesday. ...